JP2023547889A - 脊椎融合を治療するための化合物、組成物、および使用の方法 - Google Patents

脊椎融合を治療するための化合物、組成物、および使用の方法 Download PDF

Info

Publication number
JP2023547889A
JP2023547889A JP2023525023A JP2023525023A JP2023547889A JP 2023547889 A JP2023547889 A JP 2023547889A JP 2023525023 A JP2023525023 A JP 2023525023A JP 2023525023 A JP2023525023 A JP 2023525023A JP 2023547889 A JP2023547889 A JP 2023547889A
Authority
JP
Japan
Prior art keywords
amino acid
acid residues
compound
sequence identity
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547889A5 (https=
JPWO2022093374A5 (https=
Inventor
ロウ，フィリップ，エス．
ロウ，スチュアート
ニールセン，ジェフリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2023547889A publication Critical patent/JP2023547889A/ja
Publication of JP2023547889A5 publication Critical patent/JP2023547889A5/ja
Publication of JPWO2022093374A5 publication Critical patent/JPWO2022093374A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023525023A 2020-10-26 2021-08-26 脊椎融合を治療するための化合物、組成物、および使用の方法 Pending JP2023547889A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105678P 2020-10-26 2020-10-26
US63/105,678 2020-10-26
US202163193753P 2021-05-27 2021-05-27
US63/193,753 2021-05-27
PCT/US2021/047827 WO2022093374A1 (en) 2020-10-26 2021-08-26 Compounds,compositions and methods of use to treat spinal fusions

Publications (3)

Publication Number Publication Date
JP2023547889A true JP2023547889A (ja) 2023-11-14
JP2023547889A5 JP2023547889A5 (https=) 2024-09-02
JPWO2022093374A5 JPWO2022093374A5 (https=) 2024-09-02

Family

ID=81383097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525023A Pending JP2023547889A (ja) 2020-10-26 2021-08-26 脊椎融合を治療するための化合物、組成物、および使用の方法

Country Status (7)

Country Link
US (1) US20230390363A1 (https=)
EP (1) EP4232075A4 (https=)
JP (1) JP2023547889A (https=)
AU (1) AU2021369193A1 (https=)
CA (1) CA3196688A1 (https=)
MX (1) MX2023004829A (https=)
WO (1) WO2022093374A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures
EP4719459A1 (en) * 2023-06-01 2026-04-08 Radius Health, Inc. Methods for identification and quantitation of abaloparatide and related peptide impurities

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020500871A (ja) * 2016-11-30 2020-01-16 パーデュー リサーチ ファウンデーション 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
JP2024506435A (ja) * 2020-10-26 2024-02-14 パーデュー リサーチ ファウンデーション 化合物、組成物、および骨折を処置するための使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
WO2019232285A1 (en) * 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020500871A (ja) * 2016-11-30 2020-01-16 パーデュー リサーチ ファウンデーション 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
JP2024506435A (ja) * 2020-10-26 2024-02-14 パーデュー リサーチ ファウンデーション 化合物、組成物、および骨折を処置するための使用方法

Also Published As

Publication number Publication date
WO2022093374A1 (en) 2022-05-05
MX2023004829A (es) 2023-07-18
CA3196688A1 (en) 2022-05-05
WO2022093374A8 (en) 2022-09-29
AU2021369193A1 (en) 2023-06-01
EP4232075A4 (en) 2024-12-18
US20230390363A1 (en) 2023-12-07
EP4232075A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
JP7418527B2 (ja) 制御放出ｐｔｈ化合物の投薬レジメン
JP7649624B2 (ja) 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
JP7059195B2 (ja) Ｐｔｈプロドラッグ
JP2023547889A (ja) 脊椎融合を治療するための化合物、組成物、および使用の方法
JP2024037994A (ja) 放出制御ｐｔｈ化合物の漸増用量設定
KR20030004375A (ko) 부갑상선 호르몬 및 부갑상선 호르몬 - 관련 단백질의수용체 조절인자
JP2024506435A (ja) 化合物、組成物、および骨折を処置するための使用方法
JP2013513647A (ja) ポリマー担体に一時的に連結された乾燥成長ホルモン組成物
US20210206820A1 (en) Targeting anabolic drugs for accelerated fracture repair
KR101964376B1 (ko) 부갑상선호르몬(parathyroid hormone, PTH)에 골조직 선택성 펩타이드가 결합되어 있는 융합 펩타이드를 포함하는 약학 조성물 및 생체재료
RU2002130203A (ru) Пептидные конъюгаты для доставки лекарственного средства
JP2009209064A (ja) 細胞増殖促進活性を有するペプチド
WO2015092792A1 (en) Pro-angiogenic peptides and peptide conjugates
CN116710068A (zh) 用于治疗脊柱融合的化合物、组合物和方法
CN116801900A (zh) 用于治疗骨折的化合物、组合物和使用方法
JP5529014B2 (ja) 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
JPWO2022093374A5 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227